Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • GLP-1 agonists

    - PMLiVE

    Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

    The company is planning to submit regulatory applications for the candidate by the end of the year

    regeneron headquarters

    Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

    The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

    - PMLiVE

    Eli Lilly announces $3bn expansion to US injectables manufacturing facility

    The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

    - PMLiVE

    Sanofi unveils plans to build €1bn insulin production base in China

    The site will focus on serving the insulin medication needs of local diabetic patients

    - PMLiVE

    Common antidiabetic drug metformin found to slow growth of precancerous cells

    The findings suggest that the drug could be used to manage squamous oesophageal cancer risk

    - PMLiVE

    Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials

    It is hoped that a once-weekly treatment option could improve adherence rates

    - PMLiVE

    Medscape Education Demonstrates Strong Education Outcomes at the American Diabetes Association 2024 Conference

    Medscape Education presented seven scientific posters at this year’s American Diabetes Association (ADA) conference in Orlando, Florida. These posters highlighted the outcomes of Medscape Education’s continuing medical education programs, which...

    Medscape Education

    - PMLiVE

    Afon Technology’s glucose monitoring device secures Junkosha award plus $25,000 prize

    The company was presented with the award in recognition of its Glucowear device

    - PMLiVE

    Researchers identify early treatment strategy for diabetic patients at risk of kidney disease

    The chronic disease is currently the leading cause of kidney failure in the UK

    - PMLiVE

    Novo Nordisk’s Awiqli receives CHMP recommendation to treat diabetes in adults

    The chronic disease is estimated to affect 415 million people worldwide

    - PMLiVE

    New type of inhibitor drug could prevent microvascular diabetic complications

    The drug could prevent conditions including diabetic eye and kidney disease in diabetes

    - PMLiVE

    Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn

    The company will gain access to a portfolio of incretin-based therapies for diabetes and obesity

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links